Paradigm Biopharmaceuticals (ASX:PAR) has completed patient enrolment in its pivotal global Phase 3 trial for Zilosul, reaching a significant operational milestone as the company shifts focus to patient follow-up, interim analysis, and the delivery of key clinical data. Knee osteoarthritis affects hundreds of millions of people worldwide, and the treatment landscape remains dominated by symptomatic interventions such as NSAIDs, intra-articular injections, and ultimately joint replacement surgery, with no approved therapies that modify the underlying disease process.

A total of 538 participants have commenced treatment in the PARA_OA_012 study, surpassing the original enrolment target of 466 patients. The additional enrollees reflect participants who were already progressing through screening when the target was reached, with eligible patients permitted to complete the process.

The randomised, double-blind, placebo-controlled trial is being conducted across 65 clinical sites spanning Australia, the United States, Hong Kong, and Moldova. It is evaluating Zilosul (iPPS) as a treatment for pain associated with knee osteoarthritis.

With enrolment now finalised, Paradigm's attention turns to treatment completion, patient follow-up, data quality assurance, and preparation for upcoming clinical readouts. Because Phase 3 is typically the final stage of clinical development before regulatory submission, these readouts will be central to determining whether Zilosul can advance toward marketing applications with regulators such as the FDA, EMA, and Australia's TGA. An interim analysis outcome is targeted for September 2026. Topline Phase 3 primary results remain on track for the first quarter of calendar year 2027.

Beyond the pivotal study, Paradigm continued to expand the scientific evidence base supporting Zilosul. Phase 2 biomarker findings from the PARA_OA_008 study were presented at the Osteoarthritis Research Society International 2026 World Congress, highlighting biological activity across cartilage degradation, inflammation, and pain pathways.

On the financial front, Paradigm strengthened its balance sheet during the quarter through a capital raising that generated approximately A$21.38 million before costs. This comprised a A$14 million institutional placement and a A$7.38 million share purchase plan.

As of June 3, 2026, Paradigm held cash and cash equivalents of approximately A$15.37 million. After quarter end, the company received a further A$5.69 million through research and development tax incentives and tax refunds, before completing a US$3 million drawdown under its convertible note facility, which added approximately A$4.6 million in capital.

Paradigm stated that it remains funded through key upcoming milestones, including the Phase 3 interim analysis and top-line results expected in early CY27.